ReviewCurrent opinion in HIV and AIDS2013
Pipeline of drugs for related diseases: tuberculosis.
Review in Current opinion in HIV and AIDS, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- A Comprehensive Review of HIV-Associated Tuberculosis: Clinical Challenges and Advances in Management.Cureus · 2024Review
- Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistantAntimicrobial agents and chemotherapy · 2024Article
- Optimizing Bedaquiline for cardiotoxicity by structure based virtual screening, DFT analysis and molecular dynamic simulation studies to identify selective MDR-TB inhibitors.In silico pharmacology · 2021Article
- Treatment Outcomes for Patients with Extensively Drug-Resistant Tuberculosis, KwaZulu-Natal and Eastern Cape Provinces, South Africa.Emerging infectious diseases · 2016Article
- Determination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimaging.Antimicrobial agents and chemotherapy · 2015Article
- The need to accelerate access to new drugs for multidrug-resistant tuberculosis.Bulletin of the World Health Organization · 2015Article
- Profile of delamanid for the treatment of multidrug-resistant tuberculosis.Drug design, development and therapy · 2015Review
- Review
- Mathematical Modelling and Tuberculosis: Advances in Diagnostics and Novel Therapies.Advances in medicine · 2015Review
- PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis.Science translational medicine · 2014Article
- Computational pharmacology of rifampin in mice: an application to dose optimization with conflicting objectives in tuberculosis treatment.Journal of pharmacokinetics and pharmacodynamics · 2014Article
- Transforming the fight against tuberculosis: targeting catalysts of transmission.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014Review
- Drivers and trajectories of resistance to new first-line drug regimens for tuberculosis.Open forum infectious diseases · 2014Article
- ATS Core Curriculum 2014: part I. Adult pulmonary medicine.Annals of the American Thoracic Society · 2014Article
- Antitubercular therapy in patients with cirrhosis: challenges and options.World journal of gastroenterology · 2014Review
- Preferential adherence to antiretroviral therapy over tuberculosis treatment: a qualitative study of drug-resistant TB/HIV co-infected patients in South Africa.Global public health · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
purpose of reviewFor the first time in decades, there are multiple new drugs in the pipeline for the treatment of tuberculosis (TB). In addition, existing drugs are being repurposed or optimized for TB with the goal of shortened treatment duration for drug-sensitive TB and safer, shorter treatments for multidrug-resistant (MDR) TB. In this review, the results of recent trials evaluating novel combination regimens for TB disease and latent TB infection are described. RECENT
findingsHigh-dose rifamycins (rifampin and rifapentine) and fluoroquinolones directly observed have treatment-shortening potential when used for drug-sensitive TB disease, and a 12-dose once-weekly regimen of rifapentine along with isoniazid effectively treats latent TB. Bedaquiline, an anti-TB drug with a novel mechanism of action, and delamanid, a nitroimidazole, are entering phase 3 trials. Both improve rates of sputum culture conversion among patients with MDR-TB. Other nitroimidazoles and oxazolidinones are in Phase 2 testing, as are combinations involving multiple new chemical entities. SUMMARY: With the resurgence of anti-TB drug discovery efforts, we now have a modestly robust pipeline of new anti-TB drugs. Several promising new regimens involving investigational and existing drugs that may be capable of shortening treatment for drug-sensitive TB and improving management of drug-resistant TB are in late-phase clinical evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.